Synairgen Share News (SNG)

Synairgen to collaborate with University of Southampton on observational study

(Sharecast News) - Drug discovery outfit Synairgen will collaborate with the University of Southampton on an observational study aimed at exploring and better understanding acute respiratory viral infections and recovery.

UK shareholder meetings calendar - next 7 days

IN BRIEF: Synairgen shares fall as loss widens on higher costs

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Records a pretax loss of GBP57.9 million in 2021, widened from GBP17.7 million in 2020, as research and development costs jump to GBP52.9 million from GBP15.5 million. Further, administrative expenses more than double to GBP5.0 million from GBP2.2 million. Explains this with its phase 3 Sprinter trial that started patient recruitment in January 2021. The trial is for SNG001, an inhaled drug for the treatment of Covid-19. Says the remainder of the research and development expenditure was used for upscaling SNG001 manufacturing development activities and procuring long lead time components.

Synairgen posts positive clinical trial data for SNG001

(Sharecast News) - Shares of Synairgen caught a bid following the release of clinical trial results which appeared to show that its SNG001 formulation against Covid-19 might lower the risk of severe disease or death in the most at risk patients.

LONDON MARKET MIDDAY: FTSE 100 edges into green but grey clouds remain

(Alliance News) - The FTSE 100 index put a toe into positive territory by midday on Monday, reclaiming all the ground lost earlier in the morning, but investors continue to fret about poor economic data from China.

IN BRIEF: Synairgen shares soar on positive analysis of SNG001

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Notes that it announced in February that its phase 3 Sprinter trial did not meet its primary endpoints of discharge from hospital and recovery. Says that the trial still showed an encouraging signal in the reduction in the relative risk of progression to severe disease or death within 35 days. Says that it performed a post hoc analysis on groups of patients recognised to be at greater risk of developing severe disease in hospital, to assess the strength of this signal. Says that the analyses showed stronger treatment effects with SNG001 in high-risk patient sub-groups, with the strongest effect observed in those who had clinical signs of compromised respiratory function. Says SNG001 significantly reduced the risk of progression to severe disease and death compared to a placebo by 70% in the per-protocol population.

Synairgen falls as patient recruitment halted on Covid-19 trial

(Sharecast News) - Inhaled antiviral treatment developer Synairgen said on Thursday that the US National Institute of Allergy and Infectious Diseases (NIAID) has halted all patient recruitment in its phase 2 and 3 Covid-19 trial, which included the assessment of its 'SNG001' treatment.

IN BRIEF: Synairgen falls as patient recruitment in US trial halted

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Says the US National Institute of Allergy & Infectious Diseases has halted all patient recruitment in its phase 2/3 Covid-19 trial. The trial included the assessment of its inhaled SNG001 drug.

AIM WINNERS & LOSERS: Synairgen sinks 18% after US Covid study halted

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

TRADING UPDATES: Next Fifteen raises GBP50 million; N Brown sales up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Synairgen asked to pause activities on Covid-19 treatment trial

(Sharecast News) - Synairgen announced on Thursday that it was pausing clinical trial activities on its 'SNG001' compound in the treatment of Covid-19, at the behest of American authorities.

AIM WINNERS & LOSERS: dotDigital plunges after profit warning

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Synairgen falls as trial for Covid treatment fails to meet endpoints

(Alliance News) - Synairgen PLC shares hit a 12-month low on Monday after the biotechnology company said that the late-stage trial of its Covid-19 treatment SNG001 did not meet primary or key secondary efficacy endpoints.

AIM WINNERS & LOSERS: Morses Club sinks on profit warning, CEO exit

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Synairgen shares plunge as Covid-19 treatment trial fails

(Sharecast News) - Synairgen announced on Monday that the international phase 3 trial of its SNG001 antiviral inhalation in patients hospitalised with Covid-19 did not meet its primary or key secondary endpoints.